"Designing Growth Strategies is in our DNA"

Antibody Drug Conjugates Market Size, Share & Industry Analysis, By Product/Target Family (HER2-directed ADCs, Nectin-4-directed ADCs, TROP2-directed ADCs, CD30-directed ADCs, and Others), By Payload Class (Topoisomerase I Inhibitor ADCs, Microtubule Inhibitor ADCs, and Others), By Disease Indication (Breast Cancer, Urothelial Cancer, Lymphoma, Lung Cancer, Ovarian Cancer, and Others), By Route of Administration (Intravenous and Others), By End User (Hospitals, Cancer Specialty Centers, Academic & Research Hospitals, Ambulatory Infusion Centers, and Others), and Regional Forecast, 2026-2034

Last Updated: May 18, 2026 | Format: PDF | Report ID: FBI116146

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Technological Advancements in Antibody Drug Conjugates
    2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
    3. New Product Launches, By Key Players
    4. Pipeline Analysis, By Key Players
    5. Regulatory & Reimbursement Scenario, By Key Countries/Region
  5. Global Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. DAIICHI SANKYO COMPANY, LIMITED
      2. AstraZeneca
      3. Pfizer Inc.
      4. Gilead Sciences, Inc.
      5. F. Hoffmann-La Roche Ltd
      6. AbbVie Inc.
      7. GSK plc
      8. RemeGen
      9. Astellas Pharma Inc.
      10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Technological Advancements in Antibody Drug Conjugates
    2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
    3. New Product Launches, By Key Players
    4. Pipeline Analysis, By Key Players
    5. Regulatory & Reimbursement Scenario, By Key Countries/Region
  5. Global Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Antibody Drug Conjugates Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product/Target Family
      1. HER2-directed ADCs
      2. Nectin-4-directed ADCs
      3. TROP2-directed ADCs
      4. CD30-directed ADCs
      5. CD79b-directed ADCs
      6. Folate Receptor Alpha-directed ADCs
      7. Others
    2. Market Analysis, Insights and Forecast – By Payload Class
      1. Topoisomerase I Inhibitor ADCs
      2. Microtubule Inhibitor ADCs
      3. Maytansinoid ADCs
      4. DNA-damaging ADCs
      5. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Breast Cancer
      2. Urothelial Cancer
      3. Lymphoma
      4. Lung Cancer
      5. Ovarian Cancer
      6. Gastric & Gastroesophageal Cancer
      7. Others
    4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Others
    5. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Cancer Specialty Centers
      3. Academic & Research Hospitals
      4. Ambulatory Infusion Centers
      5. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. DAIICHI SANKYO COMPANY, LIMITED
      2. AstraZeneca
      3. Pfizer Inc.
      4. Gilead Sciences, Inc.
      5. F. Hoffmann-La Roche Ltd
      6. AbbVie Inc.
      7. GSK plc
      8. RemeGen
      9. Astellas Pharma Inc.
      10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Read Less

Figure 1:  Global Antibody Drug Conjugates Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034

Figure 2:  Global Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025 & 2034

Figure 3:  Global Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025 & 2034

Figure 4:  Global Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025 & 2034

Figure 5:  Global Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025 & 2034

Figure 6:  Global Antibody Drug Conjugates Market Value Share (%), By End User, 2025 & 2034

Figure 7:  Global Antibody Drug Conjugates Market Value Share (%), By Region, 2025 & 2034

Figure 8:  North America Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034

Figure 9:  North America Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025

Figure 10:  North America Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034

Figure 11:  North America Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025

Figure 12:  North America Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 13:  North America Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025

Figure 14:  North America Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034

Figure 15:  North America Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025

Figure 16:  North America Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034

Figure 17:  North America Antibody Drug Conjugates Market Value Share (%), By End User, 2025

Figure 18:  North America Antibody Drug Conjugates Market Value (USD billion), by Country, 2025 & 2034

Figure 19:  North America Antibody Drug Conjugates Market Value Share (%), by Country, 2025

Figure 20:  Europe Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034

Figure 21:  Europe Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025

Figure 22:  Europe Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034

Figure 23:  Europe Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025

Figure 24:  Europe Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 25:  Europe Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025

Figure 26:  Europe Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034

Figure 27:  Europe Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025

Figure 28:  Europe Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034

Figure 29:  Europe Antibody Drug Conjugates Market Value Share (%), By End User, 2025

Figure 30:  Europe Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 31:  Europe Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025

Figure 32:  Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034

Figure 33:  Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025

Figure 34:  Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034

Figure 35:  Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025

Figure 36:  Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 37:  Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025

Figure 38:  Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034

Figure 39:  Asia Pacific Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025

Figure 40:  Asia Pacific Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034

Figure 41:  Asia Pacific Antibody Drug Conjugates Market Value Share (%), By End User, 2025

Figure 42:  Asia Pacific Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 43:  Asia Pacific Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025

Figure 44:  Latin America Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034

Figure 45:  Latin America Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025

Figure 46:  Latin America Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034

Figure 47:  Latin America Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025

Figure 48:  Latin America Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 49:  Latin America Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025

Figure 50:  Latin America Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034

Figure 51:  Latin America Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025

Figure 52:  Latin America Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034

Figure 53:  Latin America Antibody Drug Conjugates Market Value Share (%), By End User, 2025

Figure 54:  Latin America Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 55:  Latin America Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025

Figure 56:  Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Product/Target Family, 2025 & 2034

Figure 57:  Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Product/Target Family, 2025

Figure 58:  Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Payload Class, 2025 & 2034

Figure 59:  Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Payload Class, 2025

Figure 60:  Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 61:  Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Disease Indication, 2025

Figure 62:  Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By Route of Administration, 2025 & 2034

Figure 63:  Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By Route of Administration, 2025

Figure 64:  Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), By End User, 2025 & 2034

Figure 65:  Middle East & Africa Antibody Drug Conjugates Market Value Share (%), By End User, 2025

Figure 66:  Middle East & Africa Antibody Drug Conjugates Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 67:  Middle East & Africa Antibody Drug Conjugates Market Value Share (%), by Country/ Sub-region, 2025

Figure 68:  Global Antibody Drug Conjugates Market Share (%), by Company, 2025

Table 1:  Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034

Table 2:  Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034

Table 3:  Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 4:  Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 5:  Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 6:  Global Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Region, 2021-2034

Table 7:  North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034

Table 8:  North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034

Table 9:  North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 10:  North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 11:  North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 12:  North America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country, 2021-2034

Table 13:  Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034

Table 14:  Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034

Table 15:  Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 16:  Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 17:  Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 18:  Europe Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 19:  Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034

Table 20:  Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034

Table 21:  Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 22:  Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 23:  Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 24:  Asia Pacific Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 25:  Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034

Table 26:  Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034

Table 27:  Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 28:  Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 29:  Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 30:  Latin America Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 31:  Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Product/Target Family, 2021-2034

Table 32:  Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Payload Class, 2021-2034

Table 33:  Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 34:  Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 35:  Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 36:  Middle East & Africa Antibody Drug Conjugates Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Antibody Drug Conjugates Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 198
Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Customize Now
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann